ReviewCells2025
Definition, Epidemiology and Pathophysiology of Lymphoedema.
Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Social determinants drive lymphedema severity and treatment adherence: evidence from a three-year retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Ionic Extracts of Magnesium Powders Promote In Vitro Lymphangiogenesis.Biomedicines · 2026Article
- Gatekeeper or Pathfinder? The Evolving Role of Lymphedema Surgeons in the Assessment of Limb Swelling.Journal of clinical medicine · 2026Article
- Integrative Transcriptomic Analysis Identifies CXCL12 as a Candidate Hub Gene Associated with CD4⁺ T-Cell Immune Network Remodeling in Secondary Lymphedema.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoedema is a physically and psychologically stressful, chronic progressive disease caused by long lasting damage or malfunction of the lymphatic drainage system. It is classified as primary when caused by a genetic predisposition (inherited or congenital) directly affecting any part of the lymphatic vascular system, or, much more often, as secondary (acquired) when caused by factors outside the lymphatic system, such as tumours or their treatment. As part of the development of an S3 guideline for the diagnosis and treatment of lymphoedema in German-speaking countries, we present here the definition of lymphoedema, its epidemiology, staging, pathophysiology, aggravating comorbidities, and differentiation from other forms of oedema or volume-increasing diseases. We refer to molecular links with obesity, present a diagram of possible pathomechanistic interactions, and finally discuss approaches for potential drug therapies. More intensive molecular genetic diagnostics of primary lymphedema seem to be gaining ground in Germany currently. We recommend further strengthening these diagnostics, as this is the only way to expand therapeutic options in the future and use existing therapies more efficiently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.